VivaVision's VVN461 Shows Promising Results in Phase 2 Trial for Non-Infectious Anterior Uveitis
• VivaVision Biotech's dual JAK1/TYK2 inhibitor VVN461 demonstrated non-inferior efficacy to prednisolone acetate in treating non-infectious anterior uveitis in a Phase 2 trial conducted across 10 clinical sites in China.
• Both 0.5% and 1.0% concentrations of VVN461 showed statistically significant improvements in anterior chamber cell grade with no substantial treatment-related adverse events, suggesting a potentially safer alternative to corticosteroids.
• The company plans to discuss Phase 3 clinical trials with Chinese regulatory authorities and request a type C meeting with the FDA, potentially advancing a new non-steroidal treatment option for the estimated 3 million uveitis patients in China.
Fruquintinib Plus Sintilimab Shows Promise in Advanced Renal Cell Carcinoma
• A Phase Ib/II trial of fruquintinib plus sintilimab demonstrates promising efficacy in both treatment-naive and previously treated advanced clear cell renal cell carcinoma (ccRCC) patients.
• In treatment-naive patients, the combination therapy achieved a confirmed objective response rate (ORR) of 68.2% with an 18-month progression-free survival rate of 59.4%.
• Previously treated patients experienced a 60.0% confirmed ORR and a median progression-free survival of 15.9 months with the fruquintinib and sintilimab regimen.
• The combination was generally well-tolerated, with manageable adverse events, supporting further investigation in the ongoing Phase III FRUSICA-02 study.
© Copyright 2025. All Rights Reserved by MedPath